Tracking dyspnea up to supplemental oxygen prescription among patients with pulmonary fibrosis

• Published in: BMC pulmonary medicine Vol. 17; no. 1; p. 152
• Main Authors: Olson, Amy L, Graney, Bridget, Baird, Susan, Churney, Tara, Fier, Kaitlin, Korn, Marjorie, McCormick, Mark, Sprunger, David, Vierzba, Thomas, Wamboldt, Frederick S, Swigris, Jeffrey J
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.11.2017; BioMed Central; BMC
• Subjects: Aged; Analysis; Dyspnea; Dyspnea - therapy; Female; Humans; Hypoxia; Linear Models; Longitudinal Studies; Lung diseases, interstitial; Male; Medical research; Middle Aged; Multivariate Analysis; Oxygen Inhalation Therapy; Proportional Hazards Models; Pulmonary fibrosis; Pulmonary Fibrosis - complications; Pulmonary Fibrosis - physiopathology; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Vital Capacity; Oxygen inhalation therapy; Hypoxia; Dyspnea; Lung diseases, interstitial; Quality of life
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-017-0497-0

Dyspnea is the hallmark symptom of pulmonary fibrosis. Supplemental oxygen (O ) is prescribed to many patients with pulmonary fibrosis in hopes of alleviating dyspnea and improving physical functioning. We used response data from the University of California San Diego Shortness of Breath Questionnaire (UCSD) which was administered monthly in the context of a longitudinal, observational study to plot a rich trajectory for dyspnea over time in patients with pulmonary fibrosis. We used other data from that study to identify clinical predictors of being prescribed O and to provide additional information for how UCSD scores could be used for clinical purposes. We used linear mixed-effects models and multivariate Cox proportional hazards to model change in dyspnea scores over time and to identify significant predictors of time-to-O -prescription among a pool of clinically-meaningful candidate variables. In the longitudinal study, all decisions, including whether or not to prescribe O , were made by subjects' treating physicians, not members of the research team. One-hundred ninety-four subjects with pulmonary fibrosis completed more than one UCSD or were prescribed O at some point during the follow-up period (N = 43). Twenty-eight of the 43 had analyzable, longitudinal data and contribute data to the longitudinal UCSD analyses. All 43 were included in the time-to-O -prescription analyses. Subjects prescribed O had more severe dyspnea at enrollment (38.4 ± 19.6 vs. 22.6 ± 18.7, p < 0.0001) and a steeper increase in UCSD scores over time (slope = 1.18 ± 0.53 vs. 0.24 ± 0.09 points per month, p = 0.02) than subjects not prescribed O . Controlling for baseline UCSD score and FVC%, subjects with a clinical summary diagnosis of idiopathic pulmonary fibrosis (IPF) were far more likely to be prescribed O than subjects with other forms of pulmonary fibrosis (hazard ratio = 4.85, (2.19, 10.74), p < 0.0001). Baseline dyspnea and rise in dyspnea over time predict timing of O prescription. Accounting for disease severity, patients with IPF are more likely than patients with other forms of pulmonary fibrosis to be prescribed O . UCSD scores provide clinically useful information; frequent administration could yield timely data on changes in disease status in patients with pulmonary fibrosis. The longitudinal study is registered on ClinicalTrials.gov ( NCT01961362 ). Registered October 9, 2013.